ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1355

Psoriatic Arthritis Incidence Among Patients Receiving Biologic Medications for Psoriasis; A Nested Case Control Study

Iftach Sagy1, Yael Shalev Rosenthal2, Naama Schwartz2 and Lev Pavlovsky2, 1Clinical Research Center, Soroka University Medical Center, Beer Sheva and Ben Gurion University of the Negev, DVIRA, Israel, 2​Rabin Medical Center, Petach Tikva, Israel

Meeting: ACR Convergence 2021

Keywords: Biologicals, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 8, 2021

Session Title: Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: The objective of this study was to investigate the effect of biological treatments for psoriasis on the incidence of psoriatic arthritis.

Methods: A retrospective cohort study using the electronic medical records of a large health maintenance organization. Patients who had received biological treatment for psoriasis and were not diagnosed with psoriatic arthritis before or at the time of biologic treatment initiation were included. Controls were matched by age at diagnosis, gender, time until treatment initiation, maximum BMI and smoking. The groups were different in most characteristics. Hence, a propensity score matching was implemented. The groups were compared via log rank test and a multivariable Cox regression.

Results: Overall, 1326 cases were included; 663 patients that had received biological treatment and 663 that had not. The Kaplan-Meier curve for the propensity score matched groups reflected a statistically significant increased risk for PsA among the control group compared to the biological treatment group. The results of the multivariable Cox regression showed that the control group had a significantly higher risk for PsA compared to the biological treatment group (adjusted HR=1.39; 95%CI: 1.03-1.87).

Conclusion: This study demonstrates a statistically and clinically significant lower risk for developing PsA among patients with psoriasis that receive biologic medications. The results suggest considering treatment with biologic medications in patients that present with significant risk factors for PsA at an earlier stage of treatment.


Disclosures: I. Sagy, None; Y. Shalev Rosenthal, None; N. Schwartz, None; L. Pavlovsky, None.

To cite this abstract in AMA style:

Sagy I, Shalev Rosenthal Y, Schwartz N, Pavlovsky L. Psoriatic Arthritis Incidence Among Patients Receiving Biologic Medications for Psoriasis; A Nested Case Control Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/psoriatic-arthritis-incidence-among-patients-receiving-biologic-medications-for-psoriasis-a-nested-case-control-study/. Accessed February 6, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/psoriatic-arthritis-incidence-among-patients-receiving-biologic-medications-for-psoriasis-a-nested-case-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences